- Home
- NAGE vs BME Comparison
NAGE vs BME Comparison
Compare NAGE & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAGE | BME |
|---|---|---|
| Founded | 1999 | N/A |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 547.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NAGE | BME |
|---|---|---|
| Price | $4.93 | $42.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.33 | N/A |
| AVG Volume (30 Days) | ★ 732.8K | 33.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.37 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $34.18 |
| 52 Week High | $14.66 | $42.63 |
Technical Indicators
Market Signals| Indicator | NAGE | BME |
|---|---|---|
| Relative Strength Index (RSI) | 26.98 | 52.09 |
| Support Level | $4.93 | $41.81 |
| Resistance Level | $5.32 | $42.63 |
| Average True Range (ATR) | 0.26 | 0.49 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 5.60 | 48.80 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.